Drugs Xagena
The European Commission has approved Herceptin ( Trastuzumab ) for patients with early-stage HER2-positive breast cancer following surgery and standard chemotherapy. The approval is based on impr ...
The FDA ( Food and Drug Administration ) has approved Tykerb ( Lapatinib ), a new targeted anti-cancer treatment, to be used in combination with Capectabine ( Xeloda ), another cancer drug, for patien ...
A new pilot study by Researchers at Memorial Sloan-Kettering Cancer Center ( MSKCC ) found that breast cancer patients can be treated safely with a dose-dense regimen of standard chemotherapy agents a ...
The FDA ( Food and Drug Administration ) has approved Kadcyla ( Trastuzumab Emtansine ), a new therapy for patients with HER2-positive, late-stage ( metastatic ) breast cancer.HER2 is a protein involv ...
The FDA ( Food and Drug Administration ) has approved Pertuzumab injection ( Perjeta ) for use in combination with Trastuzumab and Docetaxel for the treatment of patients with HER2-positive metastatic ...
The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Tyverb ( Lapat ...
Roche has announced that Kadcyla ( Trastuzumab emtansine or T-DM1 ) has been approved by the European Commission for people with previously treated HER2-positive advanced breast cancer.Specifically, K ...
The ASCO Task Force has applied the Framework to four clinical scenarios in which multiple trials have compared new treatment options with current standards of care: first-line treatment for metastati ...
The Chemotherapy Clinical Reference Group ( CRG ) has reviewed drugs and drug indications for inclusion on the National cancer drugs fund list. The decision summaries record how each drug/drug indica ...
The FDA ( U.S. Food and Drug Administration ) has approved Nerlynx ( Neratinib ) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer. For patients with this type of cance ...
The Food and Drug Administration ( FDA ) has approved a new fixed-dose combination of Pertuzumab, Trastuzumab, and Hyaluronidase–zzxf ( Phesgo ) for subcutaneous injection for the following indicatio ...
The European Commission ( EC ) has granted marketing authorization for Tukysa ( Tucatinib ) in combination with Trastuzumab and Capecitabine for the treatment of adult patients with HER2-positive loca ...
The FDA ( Food and Drug Administration ) has approved Enhertu ( fam-Trastuzumab Deruxtecan-nxki; fam-Trastuzumab Deruxtecan ) for adult patients with locally advanced or metastatic HER2-positive gastr ...
The Food and Drug Administration ( FDA ) has approved Enhertu ( fam-Trastuzumab Deruxtecan-nxki; Trastuzumab Deruxtecan ) for adult patients with unresectable or metastatic HER2-low ( IHC 1+ or IHC 2+ ...
The Food and Drug Administration ( FDA ) has approved Margenza ( Margetuximab-cmkb; Margetuximab ) in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive b ...
The FDA ( U.S. Food and Drug Administration ) has approved Tukysa ( Tucatinib ) in combination with chemotherapy ( Capecitabine ) and Trastuzumab for the treatment of adult patients with advanced form ...
DESTINY-Breast04 was a phase III, randomized, open-label multicenter, global trial in adult patients with unresectable or metastatic HER2-low breast cancer, which was defined as tumors scoring 1+ or 2 ...
